治疗持续时间对宫癌结局的影响,同时进行化学辐射
L Thasanthan1, A J Hilmi2, S Rosairo3
1Department of Radiography/ Radiotherapy, Faculty of Allied Health Sciences, University of Peradeniya, Peradeniya, Sri Lanka. 20400.
Radiography (London, England : 1995)
|March 4, 2026
概括
经过化疗辐射的宫癌患者的长时间治疗对生存结果产生负面影响. 在75天内完成治疗对于改善整体生存率和无病生存率至关重要.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 妇科瘤学 妇科瘤学
背景情况:
- 治疗时间是影响子宫癌结果的关键因素.
- 同时化学辐射 (CCRT) 是宫癌的标准治疗方法.
- 关于CCRT持续时间对生存时间的影响需要进一步研究.
研究的目的:
- 评估治疗时间对宫癌患者的整体生存期 (OS) 和无病生存期 (DFS) 的影响.
- 为了确定长时间的CCRT是否与较差的生存结果有关.
- 确定接受CCRT的宫癌患者的最佳治疗持续时间.
主要方法:
- 对82名宫癌患者进行了回顾性分析,这些患者接受了治疗意图的CCRT治疗.
- 患者接受了外部光束放射治疗,胸膜疗法和每周一次西斯.
- 卡普兰-梅尔分析和考克斯比例危险模型被用于评估OS和DFS,治疗的中位数持续时间为75天.
主要成果:
- 治疗持续时间>75天的患者显示显著恶化OS (HR6.54,p<0.001) 和DFS (HR3.68,p<0.001).
- 治疗延迟,主要是在手臂治疗开始时,导致治疗持续时间延长.
- 在75天内完成CCRT与改善的生存结果有关.
结论:
- 治疗延长会对接受CCRT的宫癌患者的OS和DFS产生不利影响.
- 及时完成治疗对于宫癌管理的最佳结果至关重要.
- 解决导致治疗延迟的可修改因素,如支臂疗法安排,可以改善预后.
相关概念视频
01:21Cancer Survival Analysis
806
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
806
02:49Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
71
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
71